tirzepatide cardiovascular In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT Tirzepatide and Cardiovascular Outcomes in

This segment accounts for over 61% of the market, with ongoing innovation aimed at refining treatments to secure favorable formulary tier placement and maintain a leading position in patient care

Prucalopride is approved by the European Medicines Agency (EMA) and the FDA for the treatment of chronic constipation

One such treatment option is the use of GLP-1 agonist drugs, which have been shown to be effective in promoting weight loss

Image credit: Alex Malt/Shutterstock.com A recent study in the Journal of Medical Internet Research examined patients experiences with off-label Ozempic use for weight loss and identified factors that influence user satisfaction and treatment discontinuation

Understanding the differences between fiber types will save you weeks of uncomfortable trial and error

there was a trend-level positive correlation with acyl-ghrelin AUC as well ( r = 0.40, p = 0.07) (Fig